EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Real-Life Use of a Protein-Sparing Modified Fast Diet by Nasogastric Tube (ProMoFasT) in Adults with Obesity: An Open-Label Randomized Controlled Trial

Elena Formisano iD, Irene Schiavetti iD, Raffaella Gradaschi, Paolo Gardella, Carlotta Romeo, Livia Pisciotta iD, Samir Giuseppe Sukkar iD

Nutrients · 2023

DOI: 10.3390/nu15224822 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2023. Verfasst von Elena Formisano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy. Hauptthemen laut MEDLINE: Obesity, Diet, Ketogenic. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Protein-sparing modified fast (PSMF) diet is a very-low-carbohydrate ketogenic diet administered to patients with obesity, which preserves lean mass and suppresses appetite as well as continuous enteral feeding. Thus, we aim to evaluate the effect of the PSMF diet administered continuously by nasogastric tube (NGT) or orally.

Methods

Patients with a body mass index (BMI) > 34.9 kg/m2 were randomly assigned to receive a whey protein PSMF formula through NGT (ProMoFasT) or orally. Data were collected at baseline and after 150 days. The endpoints were assessed in the intention-to-treat population.

Results

We enrolled 20 patients in the ProMoFasT group and 24 in the oral group. No differences in body weight, BMI or waist circumference between the two groups were found after 150 days. At follow-up, FFM (%) and MM (%) results were higher in the ProMoFasT group than the oral group (63.1% vs. 52.9%, p = 0.012 and 45.0% vs. 36.1%, p = 0.009, respectively) and FM (kg) and FM (%) were significantly lower in the ProMoFasT group (36.9 kg vs. 44.0 kg, p = 0.033 and 37.4% vs. 44.9%, p = 0.012, respectively). Insulin levels were lower in the ProMoFasT group than the oral group at follow-up (11.8 mU/L vs. 28.0 mU/L, p = 0.001, respectively).

Conclusion

The ProMoFasT is more effective in improving body composition and glucometabolic markers than the same diet administered orally.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityDiet, KetogenicHumansAdultBody WeightBody Mass IndexBody CompositionDiet, Carbohydrate-Restricted

Stichwörter der Autor:innen

VLCKDcontinuous enteral feedingprotein-sparing modified fastsevere obesityweight losswhey protein

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Genoa, 16132 Genoa, Italy.
  • Dietetics and Clinical Nutrition Unit, IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy.
  • Department of Health Sciences, Section of Biostatistics, University of Genova, 16132 Genova, Italy.

ORCID-Profile: Elena Formisano, Irene Schiavetti, Livia Pisciotta, Samir Giuseppe Sukkar

Zitieren

APA

Formisano, E., Schiavetti, I., Gradaschi, R., Gardella, P., Romeo, C., Pisciotta, L., & Sukkar, S. G. (2023). The Real-Life Use of a Protein-Sparing Modified Fast Diet by Nasogastric Tube (ProMoFasT) in Adults with Obesity: An Open-Label Randomized Controlled Trial. Nutrients. https://doi.org/10.3390/nu15224822

Vancouver

Formisano E, Schiavetti I, Gradaschi R, Gardella P, Romeo C, Pisciotta L, et al. The Real-Life Use of a Protein-Sparing Modified Fast Diet by Nasogastric Tube (ProMoFasT) in Adults with Obesity: An Open-Label Randomized Controlled Trial. Nutrients. 2023. doi:10.3390/nu15224822

BibTeX
@article{Formisano2023,
  author = {Formisano, Elena and Schiavetti, Irene and Gradaschi, Raffaella and Gardella, Paolo and Romeo, Carlotta and Pisciotta, Livia and Sukkar, Samir Giuseppe},
  title = {The Real-Life Use of a Protein-Sparing Modified Fast Diet by Nasogastric Tube (ProMoFasT) in Adults with Obesity: An Open-Label Randomized Controlled Trial},
  journal = {Nutrients},
  year = {2023},
  doi = {10.3390/nu15224822}
}
Kostenlos starten →